Despite exciting progress in the biology underlying a variety of proposed molecular medicines, an unmet challenge Remains—delivery. This problem, how to better target the new generation of therapeutics, cuts across all diseases. The solution offers unprecedented opportunities for multidisciplinary teams of bioengineers to work with biological and medical scientists to realize the fruits of our nation's investment in molecular and cellular medicine.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Development of a multiphase perfusion model for biomimetic reduced-order dense tumors
Experimental and Computational Multiphase Flow Open Access 05 March 2023
-
Nanoparticles for Cancer Therapy: Current Progress and Challenges
Nanoscale Research Letters Open Access 05 December 2021
-
Proof of concept of a multimodal intravital molecular imaging system for tumour transpathology investigation
European Journal of Nuclear Medicine and Molecular Imaging Open Access 15 October 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jain, R.K. Delivery of Molecular Medicine to Solid Tumors. Science 271, 1079–1080 (1996).
Klausner, R.D., The Nation's Investment in Cancer Research: A Budget Proposal for Fiscal Year 1999. National Cancer Institute (September 1997).
Jain, R.K. 1996 Eugene M. Landis Award Lecture: Delivery of Molecular and Cellular Medicine to Solid Tumors. Microcirculation 4, 1–23 (1997).
Jain, R.K., Schlenger, K., Höckel, M. & Yuan, F. Quantitative Angiofenesis Assays: Progress and Problems. Nature Med. 3, 1203–1208 (1997).
Fidler, I.J. Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl. Cancer Inst. 87, 1588–1592 (1995).
Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 6, 353–64 (1996).
Kerbel, R.S. A cancer therapy resistant to resistance. Nature 390, 335–336 (1997).
Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377–380 (1998).
Baxter, L.T., Zhu, H., Butler, W.F., Mackensen, D.G. & Jain, R.K. Biodistribution of monoclonal antibodies: scale-up from mouse to man using a physiologically-based pharmacokinetic model. Cancer Res. 55, 4611–4622 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jain, R. The next frontier of molecular medicine: Delivery of therapeutics. Nat Med 4, 655–657 (1998). https://doi.org/10.1038/nm0698-655
Issue Date:
DOI: https://doi.org/10.1038/nm0698-655
This article is cited by
-
Development of a multiphase perfusion model for biomimetic reduced-order dense tumors
Experimental and Computational Multiphase Flow (2023)
-
Proof of concept of a multimodal intravital molecular imaging system for tumour transpathology investigation
European Journal of Nuclear Medicine and Molecular Imaging (2022)
-
Nanoparticles for Cancer Therapy: Current Progress and Challenges
Nanoscale Research Letters (2021)
-
Pharmacological evaluation of prophylactic anti-microbial use in laparoscopic cholecystectomy; an open labelled study evaluating the concentrations of single dose intravenous ceftriaxone at serum and tissue level
European Journal of Clinical Pharmacology (2021)
-
Antibiotic prophylaxis and surgical site infections; a prospective open label study to clinically evaluate the serum and tissue concentration of single dose prophylactic ceftriaxone in laparoscopic cholecystectomy
European Journal of Clinical Pharmacology (2020)